TRAVERE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.565 USD | +3.55% |
|
-2.81% | -27.03% |
Chart calendar Travere Therapeutics, Inc.
2b679843.5zK3_d5H9b_sHAy7dcGiPKDlHrZSPM4jFcVeBjW3DyM.rnDhm7x0lNOOKEL4GvPMauKtb-EWerxTTPAcSF7DZ02CBtCX6wSj2o53QQ~a741600d9d404e815615083c1e4e51ec
Upcoming events on Travere Therapeutics, Inc.
Past events on Travere Therapeutics, Inc.
| 2024-05-08 | Annual General Meeting |
| 2024-05-06 04:30 pm | Q1 2024 Earnings Call |
| 2024-05-06 04:01 pm | Q1 2024 Earnings Release |
| 2024-04-18 05:15 pm | Genetic Metabolic Dieticians International Meeting - Poster Number: 33 |
| 2024-04-18 04:30 pm | Genetic Metabolic Dieticians International Meeting - Poster Number: 16 |
| 2024-04-18 04:30 pm | Genetic Metabolic Dieticians International Meeting - Poster Number: 10 |
| 2024-04-16 08:45 am | American Nephrology Nurses Association National Symposium |
| 2024-04-15 07:00 pm | Society for Inherited Metabolic Disorders Meeting - Poster Number: 68 |
| 2024-04-15 07:00 pm | Society for Inherited Metabolic Disorders Meeting - Poster Number: 48 |
| 2024-04-15 07:00 pm | Society for Inherited Metabolic Disorders Meeting - Poster Number: 64 |
| 2024-04-15 | Society for Inherited Metabolic Disorders Meeting - Poster Number: 147 |
| 2024-04-15 | Society for Inherited Metabolic Disorders Meeting - Poster Number: 139 |
| 2024-04-15 02:35 pm | Nephrology World Congress - Poster No: MON-296 |
| 2024-04-15 08:45 am | American Nephrology Nurses Association National Symposium |
| 2024-04-14 04:45 pm | Nephrology World Congress - Poster No:SUN-048 |
| 2024-04-14 04:45 pm | Nephrology World Congress - Poster No:SUN-045 |
| 2024-04-14 04:45 pm | Nephrology World Congress - Poster No:SUN-049 |
| 2024-04-14 04:45 pm | Nephrology World Congress - Poster No: SUN-042 |
| 2024-03-12 02:05 pm | Barclays Global Healthcare Conference |
| 2024-03-11 01:20 pm | Leerink Partners Global Biopharma Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 175 175 0.02% | 198 199 -0.1% | 227 223 1.95% | 212 208 2.13% | 145 195 -25.67% | 225 |
|
EBITDA Million USD | Released Forecast Spread | -117 -112 -4.34% | -152 -62,0 -144.63% | -135 -153 11.45% | -233 -246 5.27% | -350 -302 -15.91% | -211 |
|
EBIT Million USD | Released Forecast Spread | -137 -133 -3.27% | -176 -82,5 -113.42% | -162 -155 -4.05% | -267 -271 1.76% | -388 -351 -10.46% | -271 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -146 -144 -1.47% | -189 -94,4 -99.94% | -180 -178 -0.68% | -278 -284 2.14% | -376 -259 -45.47% | -269 |
|
Net income Million USD | Released Forecast Spread | -146 -141 -3.57% | -169 -74,1 -128.75% | -180 -177 -1.6% | -278 -281 0.88% | -111 -152 26.78% | -283 |
|
EPS USD | Released Forecast Spread | -3,46 -3,41 -1.54% | -3,56 -1,47 -141.45% | -3,01 -2,98 -0.91% | -4,37 -4,40 0.59% | -1,50 -2,05 26.67% | -3,38 |
| Announcement Date | 24/02/20 | 01/03/21 | 24/02/22 | 23/02/23 | 15/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 48,5 51,9 -6.61% | 54,2 49,6 9.25% | 53,5 54,1 -1.15% | 55,9 53,0 5.37% | 57,0 50,6 12.62% | 59,7 53,6 11.37% | 37,1 56,5 -34.29% | 45,1 41,8 7.76% | 41,4 43,6 -5.14% | 53,4 | 60,1 | 69,0 | 54,8 | 66,8 |
|
EBITDA Million USD | Released Forecast Spread | -59,0 -51,4 -14.92% | -57,3 -49,2 -16.64% | -59,6 -53,7 -10.93% | -57,6 -60,8 5.28% | -77,5 -72,4 -7.1% | -87,0 -75,6 -15.06% | -84,7 -88,4 4.12% | -129 -66,2 -95.36% | -54,7 | -43,6 | -36,9 | |||
|
EBIT Million USD | Released Forecast Spread | -66,1 -45,0 -46.98% | -65,5 -54,6 -19.81% | -68,1 -54,4 -25.26% | -66,9 -70,4 4.98% | -87,0 -77,9 -11.78% | -87,6 -86,2 -1.55% | -92,6 -53,7 -72.56% | -94,2 -91,8 -2.66% | -139 -79,3 -75.5% | -69,2 | -54,1 | -50,9 | -49,6 | -40,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -75,9 -50,6 -49.99% | -67,0 -60,4 -10.91% | -69,5 -57,4 -21.14% | -65,8 -72,7 9.55% | -86,3 -80,3 -7.43% | -85,6 -88,2 2.97% | -89,2 -10,8 -725.52% | -88,5 -95,0 6.85% | -136 -78,6 -72.78% | -69,4 | -53,8 | -51,5 | -49,6 | -40,7 |
|
Net income Million USD | Released Forecast Spread | -76,0 -53,0 -43.28% | -67,0 -58,0 -15.62% | -69,7 -56,8 -22.67% | -65,8 -69,6 5.41% | -86,3 -87,6 1.5% | -85,6 -85,2 -0.5% | 151 -18,9 899.39% | -90,2 -94,1 4.12% | -136 -78,3 -73.69% | -66,2 | -52,1 | -45,4 | -49,1 | -39,4 |
|
EPS USD | Released Forecast Spread | -1,20 -0,85 -40.94% | -1,05 -0,91 -15.07% | -1,09 -0,89 -22.87% | -1,03 -1,07 4.14% | -1,27 -1,19 -6.39% | -1,13 -1,16 2.98% | 1,97 -0,26 860.94% | -1,18 -1,21 2.43% | -1,76 -0,99 -77.61% | -0,84 | -0,67 | -0,58 | -0,54 | -0,48 |
| Announcement Date | 05/05/22 | 04/08/22 | 27/10/22 | 23/02/23 | 04/05/23 | 03/08/23 | 07/11/23 | 15/02/24 | 06/05/24 | - | - | - | - | - |
| 2024-05-14 | CELCUITY INC.: Q1 2024 Earnings Release |
| 2024-05-15 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 09:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-07-23 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-25 01:00 am | ARGENX SE: Q2 2024 Earnings Release |
| 2024-07-29 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-29 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Travere Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TVTX Stock
- Calendar Travere Therapeutics, Inc.
